

American Society of Clinical Oncology's Policies and Procedures for Commercial Reprints, Including Meeting Abstracts January 2008

The following considerations and requirements apply to reprints of American Society of Clinical Oncology (ASCO) content.

Printed Formats

Added Content or Elements

1. Advertised products, added graphics, added trademarks, added or changed text, stickers, customer logos, company names, product names, or product symbols on the front cover are not permitted. The back of the reprint may include a statement, "Compliments of xxx" or "Provided by xxx" in type no larger than 10 points and no smaller than 8 points. This line can be placed immediately under ASCO's disclaimer (see below).
2. Product information may be bound into the reprint as the last page(s). Promotional literature must be handled as a loose-leaf insert, a paper banded insert, or a pocket folder. The design of any band or folder must be approved by ASCO. Bands may be no larger than 2 inches in height.
3. Accompanying materials (e.g., a letter, product information pages) may not indicate or imply that ASCO, its periodicals, or its Web sites are recommending, supporting, or endorsing the customer's product(s)/program(s)/publications.

Disclaimers

1. Any legally required disclaimers on the part of the customer, usually two to four sentences only, may be printed at the top/bottom of the first/last page of the reprint provided the disclaimer(s) is/are enclosed in a box, oval, or diamond to set off the disclaimer(s) from the text. Such disclaimers may appear on the front or back cover or inside the front cover of the reprint. Type may be no larger than 10 points and no smaller than 8 points. Requests to print longer disclaimers owing to regulatory requirements will be addressed on a case-by-case basis. Each project must be reviewed by ASCO for approval.
2. The following ASCO-approved disclaimer must be placed on the last page of the article reprint:

The ideas and opinions expressed in <Title of Periodical> do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or

limitations of any products. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.

3. If the article is translated, the following disclaimer must be printed in both English and the translated language in type no larger than 10 points and no smaller than 8 points:

The ideas and opinions expressed in <Title of Periodical>do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The authors, editors, and ASCO are not responsible for errors or omissions in translations. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.

Additional Uses

Inclusion of ASCO material in a compilation with materials from other sources or organizations must be reviewed and approved by ASCO to avoid potential conflicts.

Permission Statement

An ASCO-approved permission statement must be placed at the top of the first page of the article reprint, e.g.,

Reprinted with permission from the American Society of Clinical Oncology
[If citation and copyright information does not appear on the first page of the article, then this information should follow the permission line.]

Compliance with Law

All reprints must be used in compliance with all applicable laws, regulations, and ethical guidelines.

Electronic Formats

The same policies apply to electronic media as printed media, with the following additions.

ASCO Content

Reprints distributed on a CD-ROM, memory stick, or other portable electronic device must be clearly identified as ASCO/[source] material in the navigation contents list.

Similarly, any product information or advertising must be clearly identified as originating from the company.

Examples of ASCO content:

- Clinical Efficacy of Lenalidomide in Patients with . . .
- American Society of Clinical Oncology Clinical Practice Guideline for . . .

Examples of Company Content:

- Prescribing information for [Product]
- Advertisement for [Product]

Added Content or Elements

1. Advertising and product information must be saved as separate files on the device. Reference citations in an advertisement may include a live link to the reprint on the device.
2. Device packaging must be reviewed and approved by ASCO staff before production is finalized.

Disclaimer

ASCO's disclaimer must be placed on the reprint as described under Printed Formats policies, and in addition, it must be created as a click-through that users see before accessing the reprint.

Usage Restrictions

1. Electronic reprints will include digital rights management protocols that allow the user to download the reprint to one computer and to print the reprint from that computer or from the device.
2. Reprint material may not be posted on Web sites without the written permission of ASCO. Links to electronic prints may be posted on company Web sites without ASCO's express permission.